GlobalData on MSN

ViiV Healthcare’s two-drug regimen as good as Biktarvy, study finds

ViiV Healthcare’s Dovato has been approved for use in the US and EU since 2019, but its sales remain overshadowed by Gilead’s Biktarvy.

ViiV Healthcare’s 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy in first-of-its-kind head-to-head study in treatment-naïve adults living with HIV

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced ...
The Pharma Letter

ViiV's Dovato matches Gilead's Biktarvy in first head-to-head HIV trial

ViiV Healthcare's two-drug HIV pill Dovato (dolutegravir/lamivudine) has matched the efficacy of Gilead's market-leading ...
GlobalData on MSN

ViiV’s two-monthly HIV jab bests daily oral drugs in African teenagers

The LATA study pitted Cabenuva against a triple therapy in teenagers aged 12 to 19 with HIV in Africa.
MedPage Today on MSN

Once-weekly drug combo for controlled HIV matches standard daily regimens

Weekly regimen has the potential to address pill fatigue, adherence challenges, researcher ...
MedPage Today on MSN

Two Drugs Matched Three for Untreated HIV

The difference between regimens met the trial's noninferiority threshold ...

ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults; alongside INSTI-powered long-acting injectable innovation …

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced new ...
Fierce Pharma

Gilead, Merck’s phase 3 data back first weekly HIV pill

Detailed phase 3 results suggest the two-drug combination of Gilead Sciences’ lenacapavir and Merck & Co.’s islatravir has ...
Business Wire

Late-Breaking Clinical Data and Real-World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts Toward Ending the Epidemic

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV ...